EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of NAT-6-321056 as a novel modulator of VEGFR2 signaling to suppress tumor angiogenesis

Xiao Lei, Wan Gong, Nadine Wiesmann-Imilowski, Chunmei Jin, Shila Prajapati, Axel Guthart, Sabine M Klauck, Mohamed Elbadawi, Letian Shan, Thomas Efferth, Xiaohua Lu

Biochemical Pharmacology · 2026

DOI: 10.1016/j.bcp.2026.118353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Xiao Lei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University Mainz, 55128 Mainz, Germany. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Signal Transduction, Angiogenesis Inhibitors, Neovascularization, Pathologic. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council, Johannes Gutenberg-Universität Mainz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular endothelial growth factor receptor 2 (VEGFR2) is a master regulator of angiogenesis and cancer progression. However, current VEGFR2 modulators face significant challenges, including off-target toxicity and acquired resistance, underscoring the urgent need for novel therapeutic agents with improved efficacy and safety profiles. Here, we reported that virtual screening of 39,442 natural products from the ZINC natural products-derived library, coupled with molecular docking and molecular dynamics (MD) simulations to evaluate the binding stability of candidate compounds, identified NAT-6-321056 as a highly promising modulator of VEGFR2 signaling. Biological evaluations demonstrated that NAT-6-321056 exerted potent inhibition on the growth of a broad spectrum of cancer cells, including both solid tumors and hematological malignancies. In EA.hy 926 endothelial cells and SK-N-DZ neuroblast cells, the compound significantly suppressed proliferation, migration, and invasion. Microscale thermophoresis (MST) confirmed direct binding of NAT-6-321056 to VEGFR2 with favorable affinity. Kinase profiling against a panel of 33 kinases indicated that NAT-6-321056 exhibited a multi-kinase modulation profile. Mechanistic studies revealed that NAT-6-321056 suppressed the expression of hypoxia-inducible factor 1-alpha (HIF-1α) and was associated with reduced VEGFR2 phosphorylation and attenuation of the downstream ERK/JNK/AKT signaling pathways. Moreover, NAT-6-321056 exhibited robust in vivo anti-angiogenic effects in both the chick chorioallantoic membrane (CAM) assay and transgenic zebrafish vascular fluorescence imaging models. Computational absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction suggested acceptable drug-like properties. Collectively, these findings demonstrated that NAT-6-321056 is a promising modulator of VEGFR2 signaling with potent anti-angiogenic activity and represents a viable candidate for cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2Signal TransductionAngiogenesis InhibitorsNeovascularization, PathologicDrug DiscoveryHumansAnimalsZebrafishCell Line, TumorMolecular Docking SimulationCell ProliferationChick EmbryoCell Movement

Stichwörter der Autor:innen

Anti-angiogenic therapyCAM assayTumor angiogenesisVEGFR2Zebrafish

Substanzen

Vascular Endothelial Growth Factor Receptor-2Angiogenesis InhibitorsKDR protein, human

Autor:innen und Institutionen

  • Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University Mainz, 55128 Mainz, Germany.
  • Fuyang Institute, Zhejiang Chinese Medical University, 311422 Hangzhou, China.
  • Department of Otorhinolaryngology, University Medical Center Mainz, 55131 Mainz, Germany; Department of Oral- and Maxillofacial Surgery, University Medical Center Mainz, 55131 Mainz, Germany.
  • Division of Cancer Genome Research, German Cancer Research Center (DKFZ), Heidelberg, National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership between DKFZ and University Hospital Heidelberg, 69120 Heidel…
  • Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University Mainz, 55128 Mainz, Germany. Electronic address: xiaohulu@uni-mainz.de.

Förderung

  • China Scholarship Council
  • Johannes Gutenberg-Universität Mainz

Zitieren

APA

Lei, X., Gong, W., Wiesmann-Imilowski, N., Jin, C., Prajapati, S., Guthart, A., Klauck, S. M., Elbadawi, M., Shan, L., Efferth, T., & Lu, X. (2026). Discovery of NAT-6-321056 as a novel modulator of VEGFR2 signaling to suppress tumor angiogenesis. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118353

Vancouver

Lei X, Gong W, Wiesmann-Imilowski N, Jin C, Prajapati S, Guthart A, et al. Discovery of NAT-6-321056 as a novel modulator of VEGFR2 signaling to suppress tumor angiogenesis. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118353

BibTeX
@article{Lei2026,
  author = {Lei, Xiao and Gong, Wan and Wiesmann-Imilowski, Nadine and Jin, Chunmei and Prajapati, Shila and Guthart, Axel and Klauck, Sabine M and Elbadawi, Mohamed and Shan, Letian and Efferth, Thomas and Lu, Xiaohua},
  title = {Discovery of NAT-6-321056 as a novel modulator of VEGFR2 signaling to suppress tumor angiogenesis},
  journal = {Biochemical Pharmacology},
  year = {2026},
  doi = {10.1016/j.bcp.2026.118353}
}
Kostenlos starten →